The Dish’s Weekly News Wrap Up – June 27, 2014

By on June 27, 2014

This week’s headlines include, pharmaceutical sales to grow through 2020, EMD Serono and Mersana join on ADCs, immunotherapy prolongs survival in melanoma trial, report finds R&D spending outpacing revenue growth, top 10 vaccines sales for 2013, world’s largest study on Dementia, Mesoblast product shows promise in trial.

Cell Culture Events

The Bioprocessing Summit – August 18-22, 2014 – Renaissance Waterfront Hotel – Boston, MA

http://www.bioprocessingsummit.com/

Cell Line Development & Engineering – September 8-10, 2014 – Doubletree by Hilton Berkeley Marina Berkeley, CA

http://www.ibclifesciences.com/CellLine/overview.xml

Cell Culture World Congress USA – September 15-16, 2014 – The Westin Copley Place – Boston, MA

http://www.terrapinn.com/conference/cell-culture-world-congress-usa/index.stm

Stem Cells Regenerative Medicine Conference

http://www.terrapinn.com/conference/stem-cells-and-regenerative-medicine-congress/#stem-cells-and-regenerative-medicine-congress

World Cord Blood Congress

http://www.terrapinn.com/conference/stem-cells-and-regenerative-medicine-congress/world-cord-blood-congress.stm#world-cord-blood-congress

Headlines:

“Biotech R&D Spending Outpaces Revenue Growth: Report,” Reuters

“For the first time since the global financial crisis began in mid-2007, spending by biotechnology companies on research and development grew at a faster rate than revenue, according to consulting firm Ernst & Young.”

If you like this story, please see our blog titled CHO Cell Culture – Ten Tips from the Experts on Expression, Media and Bioprocessing

“Top 10 Best-Selling Vaccines of 2013,” Genetic Engineering News

“Recent advances in the quest for vaccines against MERS, SARS, and other coronaviruses have vaccines front and center in the news again. More ominously, scientists have demonstrated that circulating avian influenza viruses contain all the genetic ingredients needed to lead to the emergence of a virus similar to the deadly 1918 influenza virus.”

If you like this story, please see our blog titled Reducing Footprints and Increasing Output in Adherent Cell Culture

“Remembering Dementia: World’s Biggest Study Gets Under Way,” The Wall Street Journal Pharmalot

“The world’s biggest dementia study was launched in the U.K. Thursday, and will analyze data from more than two million people to try and find new treatments for the little-understood disease, including its commonest form, Alzheimer’s.”

If you like this story, please see our blog titled “Single-use Technology for Microbial Fermentation

“Report: Pharmaceutical Sales to Grow 5.1% on Average Through 2020,” Drug Store News

“Worldwide prescription drug sales are expected to exceed the trillion dollar mark by 2020, according to Evaluate’s “World Preview 2014, Outlook to 2020” report released Wednesday. Evaluate projects the pharma industry to grow, on average, 5.1% per year from 2013 to 2020.”

If you like this story, please see our blog titled “PCR Release Testing for Mycoplasmas Gaining Ground versus Conventional Methods

“Mesoblast’s MPCs Show Promise in Type 2 Diabetes,” Australian Life Scientist

“Mesoblast mesenchymal precursor cells (MPCs) improved glycaemic control and reduced blood glucose levels in patients with type 2 diabetes during a phase II trial.”

If you like this story, please see our blog titled Part II – Key Tools and Technology Hurdles in Advancing Stem-Cell Therapies

“EMD Serono, Mersana Join to Develop ADCs in up to $7.92 M Deal,” Genetic Engineering News

“Mersana Therapeutics and Merck KGaA’sEMD Serono subsidiary will team up to developantibody-drug conjugates (ADCs) using Mersana’s Fleximer® technology. The deal could net Mersana up to $792 million in upfront and milestone payments, as well as royalties on worldwide net sales.

If you like this story, please see our blog titled Aastrom CEO Discusses How Recent Acquisition Strengthens Current Manufacturing Capability and Clinical Pipeline

“Bristol Immunotherapy Prolongs Survival in Melanoma Trial,” News Daily

“A late stage trial testing Bristol-Myers Squibb Co’s cancer immunotherapy nivolumab in advanced melanoma patients was halted early after it was determined that the drug was likely to prolong survival, the company said on Tuesday.”

If you like this story, please see our blog titled “Using Induced Pluripotent Stem Cells to Model Human Disease

Leave a Reply

Your email address will not be published. Required fields are marked *